Literature DB >> 6682760

Purification and characterization of a melanoma cell plasminogen activator.

P Wallén, G Pohl, N Bergsdorf, M Rånby, T Ny, H Jörnvall.   

Abstract

The plasminogen activator from a human melanoma cell line was purified with immunoadsorption as a major step. The cells were cultured in the presence of aprotinin in order to avoid proteolysis. A three-step purification involved adsorption on antibodies to porcine tissue plasminogen activator before chromatographies on arginine-Sepharose and Sephadex G-150. All solvents contained Tween-80 (0.01%) and, except for the last step, aprotinin. The final product had a specific activity of about 220000 IU/mg measured against the WHO urokinase standard. The activator obtained has an apparent Mr of 72000 and consists of single-chain molecules. Evidence was obtained that four different types of activator variants occur. First and known previously, the one-chain form can be proteolytically cleaved into a two-chain form. Secondly, both the one-chain and two-chain molecules exhibit two forms with molecular weight differences of about 3000 (possibly due to carbohydrate differences). Thirdly, the one-chain preparations contain two variants, each constituting about 50% of the material and differing in length by three N-terminal amino acids. Finally, a possible positional microheterogeneity was detected. Digestion with plasmin yields the two-chain form with disulfide-bonded polypeptide chains, 'A' and 'B' (from the N-terminal and C-terminal parts, respectively). At the same time, the variability of the original N terminus is removed. The A chain keeps the two Mr variants (now about 40000 and 37000, respectively). The B chain (Mr about 33000) contains the active site of the molecule, as demonstrated by labelling with [3H]diisopropyl phosphofluoridate, and is homologous to the enzymatically active chains of thrombin, plasmin and other serine proteases. In contrast to these enzymes, the plasminogen activator is enzymatically active in the one-chain form. A speculative explanation for this activity may possibly be the presence of an epsilon-amino group of a lysine residue at a position close to the bond cleaved in the two-chain form.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682760     DOI: 10.1111/j.1432-1033.1983.tb07418.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  15 in total

1.  Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

Authors:  D C Rijken; J J Emeis
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

Review 2.  Translational initiatives in thrombolytic therapy.

Authors:  Melvin E Klegerman
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

3.  Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA.

Authors:  M Renatus; R A Engh; M T Stubbs; R Huber; S Fischer; U Kohnert; W Bode
Journal:  EMBO J       Date:  1997-08-15       Impact factor: 11.598

Review 4.  Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

Authors:  D Collen; H R Lijnen; P A Todd; K L Goa
Journal:  Drugs       Date:  1989-09       Impact factor: 9.546

5.  The structure of the human tissue-type plasminogen activator gene: correlation of intron and exon structures to functional and structural domains.

Authors:  T Ny; F Elgh; B Lund
Journal:  Proc Natl Acad Sci U S A       Date:  1984-09       Impact factor: 11.205

6.  Binding of tissue plasminogen activator to human endothelial cells. Importance of the B-chain as a ligand.

Authors:  X F Cheng; O Bäck; T K Nilsson; E Nylander Lundqvist; G Pohl; P Wallén
Journal:  Biochem J       Date:  1992-10-15       Impact factor: 3.857

7.  An evaluation of different enzymatic cleavage methods for recombinant fusion proteins, applied on des(1-3)insulin-like growth factor I.

Authors:  G Forsberg; B Baastrup; H Rondahl; E Holmgren; G Pohl; M Hartmanis; M Lake
Journal:  J Protein Chem       Date:  1992-04

8.  Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins.

Authors:  J Mordenti; S A Chen; J A Moore; B L Ferraiolo; J D Green
Journal:  Pharm Res       Date:  1991-11       Impact factor: 4.200

9.  Expression of human dopamine beta-hydroxylase in Drosophila Schneider 2 cells.

Authors:  B Li; S Tsing; A H Kosaka; B Nguyen; E G Osen; C Bach; H Chan; J Barnett
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

10.  The glycosylation of Bowes melanoma tissue plasminogen activator: lectin mapping, reaction with anti-L2/HNK-1 antibodies and the presence of sulphated/glucuronic acid containing glycans.

Authors:  A J Jaques; G Opdenakker; T W Rademacher; R A Dwek; S E Zamze
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.